Open Access Repository
Technology evaluation: MRA, Chugai
Download Statistics
Download Statistics
Download StatisticsDownloads
Downloads per month over past year
Ding, C and Jones, G 2003
, 'Technology evaluation: MRA, Chugai'
, Current Opinion in Molecular Therapeutics, vol. 5, no. 1
, pp. 64-69
.
|
PDF
MRA.PDF | Download (52kB) Available under University of Tasmania Standard License. | Preview |
Official URL: http://www.biomedcentral.com/1464-8431/5?issue=1
Abstract
Chugai, the Japanese subsidiary of Roche, is developing a
humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
| Item Type: | Article |
|---|---|
| Authors/Creators: | Ding, C and Jones, G |
| Journal or Publication Title: | Current Opinion in Molecular Therapeutics |
| ISSN: | 1464-8431 |
| Item Statistics: | View statistics for this item |
Actions (login required)
 |
Item Control Page |